NFKB1 and cancer: SL-derived drugs, such as parthenolide (PTL) (20) (an inhibitor of the NF-κB signaling pathway that induces apoptosis in cancer stem cells), thapsigargin (21) (a potent sarcoplasmic/endoplasmic reticulum Ca+2 ATPase (SERCA) pump inhibitor), and artemisinin (22), a cadinanolide with anti-inflammatory, antimicrobial, and anti-malarial properties, are now being explored as anticancer drugs [25,26,27].